The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nizar Bahlis, University of Calgary, Calgary, CA, answers the question: Does the combination of venetoclax, daratumumab, dexamethasone, with or without bortezomib, represent a new treatment option for patients with relapsed/refractory myeloma?
Nizar Bahlis talk about the M1564 trial that looks at daratumumab combined with venetoclax, with or without bortezomib in patients with relapsed multiple myeloma. He discussed the potential of bortezomib being able to sensitize patients to the effect of venetoclax treatment. He explains the overall response rates of patients in this study